Dr. Joel G Moranz, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 300 Evergreen Dr, Suite 170, Glen Mills, PA 19342 Phone: 610-521-4311 Fax: 610-521-5995 |
Dr. Arthur Terry Laver, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 300 Evergreen Dr, Suite 150, Glen Mills, PA 19342 Phone: 610-579-3489 |
Julia Palalay Ngayan, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 435 Concord Rd, Glen Mills, PA 19342 Phone: 610-459-2173 Fax: 610-459-9031 |
News Archive
Ohr Pharmaceutical Inc., announced that interim data from the company's ongoing Phase II clinical trial of OHR/AVR118 for the treatment of Cachexia, will be presented at the 5th annual meeting of the Society on Cachexia and Wasting Disorders (SCWD), which will be held in Barcelona December 5 - December 8, 2009.
AOptix Technologies, Inc., a leading-edge developer of advanced iris biometrics products and long-distance wireless optical communications solutions, today announced that AOptix and Aware, Inc. will be demonstrating a prototype dual-factor iris and face biometrics system in the AOptix exhibition booth at the upcoming Biometrics Consortium Conference and Technology Expo. The event takes place in Tampa from September 21 to 23, 2010.
Traumatic brain injuries from sports, recreational activities, falls or car accidents are the leading cause of death and disability in children and adolescents. While previously it was believed that the window for brain recovery was at most one year after injury, new research from the Center for BrainHealth at The University of Texas at Dallas published online today in the open-access journal Frontiers in Neurology shows cognitive performance can be improved to significant degrees months, and even years, after injury, given targeted brain training.
The Y chromosome retains a remarkable record of human ancestry, since it is passed directly from father to son.
Despite the advent of numerous vaccines and the discovery of passive monoclonal antibodies for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there remains an urgent need for definitive therapies for coronavirus disease-2019 (COVID-19) patients.
› Verified 4 days ago